Business Context and Reporting Period
Company: NOVAVAX INC
Filing Type: Form 8-K (Current Report)
Date of Report: February 12, 2021
Event: Entry into a Material Definitive Agreement (Item 1.01)
Key Financial Metrics
This filing is a current report regarding a strategic agreement and does not contain audited financial statements, revenue figures, profit margins, cash flow data, or debt levels. The filing text does not provide a clear value for these metrics.
Material Changes and Agreement Details
On February 12, 2021, Novavax entered into a Collaboration and License Agreement with SK bioscience Co., Ltd. Key terms include:
- Exclusive License: SK bioscience received an exclusive license to develop, manufacture, and commercialize Novavax's SARS-CoV-2 vaccine candidate (NVX-CoV2373) in the Republic of Korea.
- Government Supply: The agreement covers the anticipated sale of 40 million doses to the Korean government under an advance purchase agreement.
- Manufacturing: SK bioscience will expand capacity to manufacture the protein antigen component and purchase finished vaccine product and Matrix-M adjuvant from Novavax for early supply.
- Financial Consideration: SK bioscience will pay a tiered royalty in the low to middle double-digit range on sales in Korea, net of certain agreed costs.
- Regulatory Responsibility: SK bioscience is solely responsible for obtaining regulatory approvals in Korea, with support from Novavax.
- Term: The agreement expires on the later of February 12, 2023, completion of obligations, or the WHO declaration that the COVID-19 pandemic has ended.
Guidance, Outlook, and Risks
Outlook: The agreement facilitates the commercialization of the vaccine in South Korea and expands manufacturing capacity for the protein antigen component.
Risks and Contingencies: The supply of finished vaccine product is subject to regulatory approval. The agreement includes customary representations, warranties, confidentiality, limitation of liability, and indemnity provisions. Oversight is managed by a joint steering committee.
Investor Verification Checklist
- Verify the specific tiered royalty percentages and "agreed costs" excluded from the royalty base in the full agreement text.
- Confirm the status of the Korean government's advance purchase agreement for 40 million doses.
- Monitor the timeline for SK bioscience's regulatory approval in the Republic of Korea.
- Review the full Collaboration and License Agreement when filed as an exhibit to the Form 10-Q for the quarter ended March 31, 2021.